

Classifying tumors by supervised network propagation

Wei Zhang^{1,*†}, Jianzhu Ma^{1,†} and Trey Ideker^{1,2,*}

¹Department of Medicine and ²Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA

*To whom correspondence should be addressed.

†The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.

Abstract

Motivation: Network propagation has been widely used to aggregate and amplify the effects of tumor mutations using knowledge of molecular interaction networks. However, propagating mutations through interactions irrelevant to cancer leads to erosion of pathway signals and complicates the identification of cancer subtypes.

Results: To address this problem we introduce a propagation algorithm, Network-Based Supervised Stratification (NBS²), which learns the mutated subnetworks underlying tumor subtypes using a supervised approach. Given an annotated molecular network and reference tumor mutation profiles for which subtypes have been predefined, NBS² is trained by adjusting the weights on interaction features such that network propagation best recovers the provided subtypes. After training, weights are fixed such that mutation profiles of new tumors can be accurately classified. We evaluate NBS² on breast and glioblastoma tumors, demonstrating that it outperforms the best network-based approaches in classifying tumors to known subtypes for these diseases. By interpreting the interaction weights, we highlight characteristic molecular pathways driving selected subtypes.

Availability and implementation: The NBS² package is freely available at: <https://github.com/wzhang1984/NBSS>.

Contact: wzhang1984@gmail.com or tideker@ucsd.edu

Supplementary information: [Supplementary data](#) are available at *Bioinformatics* online.

1 Introduction

The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) have recently used exome or genome-wide DNA sequencing to construct very large catalogs of somatic mutations found in tumors of many types (International Cancer Genome Consortium *et al.*, 2010; Weinstein *et al.*, 2013). Analysis of these data has shown the striking observation that, while a few genes are mutated frequently in cancer, most mutations fall in genes which are mutated quite rarely. That is, the somatic mutation profiles of tumors are fundamentally heterogeneous, with few commonalities and many differences found among and within different cancers.

A popular approach to interpret and reduce this heterogeneity has been to aggregate tumor mutations in the context of molecular networks. Various approaches have been developed based on this principle, including identification of subnetworks that aggregate mutations in different genes across a cohort (e.g. HotNet2) (Leiserson *et al.*, 2015a; Ruffalo *et al.*, 2015; Horn *et al.*, 2018; Miller *et al.*, 2011; Creixell *et al.*, 2015b; Bertrand *et al.*, 2015) or identification of tumor subtypes (e.g. network-based stratification,

aka NBS) (Hofree *et al.*, 2013; Kim *et al.*, 2016; Jin *et al.*, 2015; Gaiteri *et al.*, 2015; Cho *et al.*, 2016). The core algorithm of these methods is network propagation (Cowen *et al.*, 2017), which uses a random walk (Pearson, 1905) model to diffuse information about gene mutations through network interactions. The rationale of this approach is that genetic alterations affecting two different, but interacting, genes have an elevated likelihood of yielding the same functional and phenotypic outcomes. The result of network propagation is typically to generate a score for each gene that captures its network proximity to genes with somatic mutations.

While such methods are promising, they face a variety of open challenges, many related to how best to detect the subnetworks (pathways) affected by mutations. In particular, the above network propagation approaches rely on reference molecular networks in the public domain which are neither tissue-specific nor cancer-specific. Propagating mutations through gene interactions not present in cancer cells can cause erroneous aggregation of passenger mutations as well as contamination of characteristic pathway signals, leading to poor tumor subtype stratification. Therefore, it is important to distinguish between interactions that are functional in tumor cells and those that are not, particularly in light of recent studies showing that

tumor cells rewire numerous molecular interactions during cell proliferation and clonal expansion (Li *et al.*, 2017; Wu *et al.*, 2009; AlQuraishi *et al.*, 2014; Creixell *et al.*, 2015c; Creixell *et al.*, 2015a).

Here, we develop Network-Based Supervised Stratification (NBS²), a general framework that extends the Supervised Random Walk algorithm (Backstrom and Leskovec, 2010) with a novel loss function designed specifically for cancer subtype classification. Similar to other cancer network approaches, network propagation is a central component for aggregation of mutations impacting the same subnetwork regions. However, unlike previous approaches, supervised learning is used to adjust the weight of each molecular interaction, guiding the direction of propagation to maximize the agreement among tumors of the same subtype. We demonstrate that this new algorithm leads to improved performance in cancer subtype stratification. Moreover, the highly weighted interactions outline biological pathways that affiliate with the underlying cancer subtypes.

2 Materials and methods

Supervised Random Walk (SRW) was originally proposed to recommend interpersonal links in social networks (Backstrom and Leskovec, 2010). From this work, we have borrowed the concept of learning an activation score for each interaction in a gene network used in the random walk process. The cost function used in supervised learning is designed specifically for cancer subtype classification. In the following sections, we first describe the methodology for the basic random walk algorithm and then extend it to a supervised approach (Fig. 1).

2.1 Unsupervised tumor stratification based on random walk

Given a graph $G = \langle V, E \rangle$, where V is the node set representing genes and E is the edge set representing molecular interactions, a Random Walk with Restart (RWR) process (Hofree *et al.*, 2013) can be conducted iteratively as follows:

$$P^{(t+1)} = (1 - \alpha)P^{(t)} \cdot Q + \alpha P^{(0)} \quad (1)$$

Here $P^{(0)}$ is a tumor-by-gene binary matrix (0=wild type; 1=mutated) representing the mutation profile of each tumor in a cohort, and Q is the degree-normalized adjacency matrix of G . The parameter α denotes the restart probability, governing the distance that mutation signal is allowed to propagate through the network. At convergence, when $P^{(t+1)} \approx P^{(t)}$, stationary random walk scores $P^{(t)}$ represent a tumor-by-gene matrix, in which the mutation profile of each tumor has been ‘smoothed’ by the network. The score of each gene represents its network proximity to all genes with mutations. $P^{(t)}$ is hereafter referred to as ‘propagated mutation profiles’. Applying non-negative factorization to these propagated mutation profiles has been shown to identify clinically meaningful tumor subtypes (Hofree *et al.*, 2013).

2.2 Supervised tumor classification based on random walk

Within the above random walk framework, we introduce the additional goal of learning a new type of adjacency matrix Q directly from data, such that the stratification of propagated mutation profiles after random walk is close to the pre-defined tumor subtypes (Fig. 1 and Section 2.3). In particular, Q in




Fig. 1. NBS² Workflow. NBS² takes three input datasets, represented by red arrows: (1) a molecular network where each edge is annotated by a feature vector x , and each feature is assigned an initial weight w ; (2) a tumor-by-gene matrix $P^{(0)}$ representing the mutation profile of a cohort and (3) the defined subtype of each tumor. In each iteration, NBS² computes an activation score a for each edge (Equation 3), calculates a transition matrix Q (Equation 2), performs a random walk (Equation 1), and computes the value of the cost function $J(w)$ (Equation 4). Training the classifier is conducted iteratively using gradient descent. To minimize $J(w)$, the algorithm calculates the gradient of $J(w)$ with respect to the edge feature weights w using the chain rule (Equations 7–11) and updates w accordingly. Upon convergence, the algorithm outputs the final feature weights w , transition matrix Q and propagated mutation profiles P , which together define the classification model

Equation (1) is replaced by a weighted transition matrix defined as follows:

$$Q_{ij} = \delta((i, j) \in E) \frac{a_{ij}}{\sum_k a_{ik}} \quad (2)$$

where δ is an indicator function which equals 1 when satisfied and 0 otherwise. The parameter a_{ij} represents the activation score for the molecular interaction between i and j and is defined as:

$$a_{ij} = \frac{1}{1 + \exp(-w^T \cdot x_{ij})} \quad (3)$$

Here a_{ij} is a sigmoid function of feature vector x_{ij} , which captures characteristics of the interaction between gene i and j , such as type of interaction (e.g. protein-protein, co-expression, kinase-substrate), source database, whether mutations at i and j are mutually exclusive, and so on (Section 2.6, Supplementary Table S1). The feature weights vector w is learned in the training phase of the algorithm. Note that, in practice we introduce an ‘intercept’ feature which is held constant at 1 for all edges. Intuitively, the learned weight of ‘intercept’ determines the ‘default’ activation score of all edges. The value of a_{ij} ranges from 0 to 1, with larger values signifying that mutation signal is more likely to traverse edge (i, j) during random walk. By normalizing a_{ij} across all nodes, each entry Q_{ij} defines the probability that a random walk will traverse edge (i, j) given it is currently at node i . However, such normalization has an unwanted property: even if the model learns that a_{ij} should be close to 0 for all network neighbors of i , the row vector $Q_{i \cdot}$ still sums to 1. Therefore, one can never truly remove all edges from node i . To overcome this limitation, we add a self-loop edge to each node, marked by an additional edge feature called ‘self-loop’. For each self-loop (i, i) , all features x_{ii} are set to 0 except for the ‘self-loop’ feature, which is set to 1.

For all other edges (i, j) , the ‘self-loop’ feature is set to 0. In this way, the algorithm can learn whether a node should be isolated or connected to others, by controlling the proportion of weight placed on the ‘self-loop’ feature versus other features.

2.3 Cost function

Instead of directly predicting the subtype label, the NBS² training process learns the center of each subtype cluster from training data. In the testing/validation phase, each patient sample is assigned to one of these subtypes based on the shortest Euclidean distance to the centers. In this way, the whole classification framework can be viewed as a supervised clustering process.

Based on this rationale, a cost function is designed to find optimal edge feature weights w such that the tumor classification error based on the propagated mutation profiles P is minimized. The optimization problem is defined as follows:

$$\min_w J(w) = \lambda \|w\|_1 + \sum_{u=1}^m \frac{1}{1 + \exp(-\beta D_u)} \quad (4)$$

$$D_u = \|p_u - c_a\|_2^2 - \min_{b \neq a} \|p_u - c_b\|_2^2 \quad (5)$$

where m is the total number of tumors; vector p_u is row u of P , representing the propagated mutation profile of all genes of tumor u ; c_a is the centroid vector of the true subtype a of tumor u provided in training data. It is defined as:

$$c_a = \frac{1}{m_a - 1} \sum_{v \in a, v \neq u} p_v \quad (6)$$

where m_a is the number of tumors in subtype a . To avoid information leak, in the training phase of the algorithm, p_u is excluded from the calculation of c_a . The second term of Equation (5) calculates the shortest distance to p_u among all the other subtypes. The intuition of Equations (4) and (5) is that we want the propagated mutation profile of tumor u to be always closer to the centroid of its own subtype than all the other subtypes. We found this objective function extremely helpful when the centroids of two cancer subtypes are close to each other. The sigmoid function in Equation (4) is used to scale the value of D_u between 0 and 1 to mimic the classification error for easier optimization (Yan et al., 2003). That is, when tumor u is closer to an incorrect subtype, which tends to drive $D_u \gg 0$, the second term of Equation (4) with respect to u is close to 1. In contrast, when tumor u is close to its own subtype, the second term is close to 0. To improve the interpretability of our model, we use the l_1 -norm to regulate model complexity (first term of Equation 4), in which case λ is the hyperparameter used to control the sparsity of parameters. We also introduce a hyperparameter β to control model nonlinearity. Large β increases the model’s ability to describe the training data but also increases the risk of overfitting. In practice, both β and λ are tuned by cross validation.

2.4 Training the classification model

The objective function defined in Equations (4) and (5) is differentiable. Therefore, we used gradient descent to find its local optimum. After calculating the gradient of each parameter, we then applied Adam (Kingma and Ba, 2014) to minimize $J(w)$. The gradient of each parameter is calculated using the chain rule. The partial derivative of $J(w)$ with respect to a particular feature weight w_l is written as:

$$\frac{\partial J(w)}{\partial w_l} = \text{sign}(w_l) \lambda + \sum_{u=1}^m \beta g(w) (1 - g(w)) \frac{\partial D_u}{\partial w_l} \quad (7)$$

where $g(w)$ is the second term of $J(w)$ in Equation 4.

$$\frac{\partial D_u}{\partial w_l} = 2(p_u - c_a)^T \cdot \left(\frac{\partial P_u}{\partial w_l} - \frac{\partial c_a}{\partial w_l} \right) - 2(p_u - c_b)^T \cdot \left(\frac{\partial P_u}{\partial w_l} - \frac{\partial c_b}{\partial w_l} \right) \quad (8)$$

Equation (8) indicates that calculating the gradient of the overall objective function first requires the gradient of matrix P , because c is also a function of P . P is calculated through an iterative process until convergence to hasten the training process (Equation 1). The partial derivative of matrix P in Equation (1) with respect to w_l can be calculated using a similar iterative update process as follows:

$$\frac{\partial P}{\partial w_l} = (1 - \alpha) \cdot \left(\frac{\partial P}{\partial w_l} \cdot Q + P \cdot \frac{\partial Q}{\partial w_l} \right) \quad (9)$$

Equation (9) is executed iteratively until the gradient of P converges. Each iteration requires the gradient of matrix Q :

$$\frac{\partial Q_{ij}}{\partial w_l} = \delta((i, j) \in E) \frac{\frac{\partial a_{ij}}{\partial w_l} \sum_k a_{ik} + a_{ij} \sum_k \frac{\partial a_{ik}}{\partial w_l}}{(\sum_k a_{ik})^2} \quad (10)$$

Here, δ is an indicator function which equals to 1 when satisfied and 0 otherwise. Using the chain rule, the partial derivative of edge activation score a_{ij} with respect to weight w_l is calculated as follows:

$$\frac{\partial a_{ij}}{\partial w_l} = x_{ijl} a_{ij} (1 - a_{ij}) \quad (11)$$

2.5 Subtype prediction for new tumors

The classification model is defined by the final transition matrix Q , parameterized by the final edge feature weights w , as well as the centroids c of all subtypes calculated from the training data. Given a new tumor z with mutation profile $P_z^{(0)}$, our goal is to predict its subtype based on the Q and c learned previously by the model. First, a propagated mutation profile P_z is calculated from $P_z^{(0)}$, using random walk based on Q (Equation 1). Then the subtype of z is predicted as follows:

$$s = \underset{s \in A}{\text{argmin}} \|p_z - c_s\|_2^2 \quad (12)$$

where A is the set of all subtypes, and s is the predicted subtype of z .

2.6 Edge features

To calculate the edge activation score (Equation 3), each edge is annotated by a set of edge features. In particular, in the analysis of real tumor mutation profiles (Sections 3.2 and 3.3), we designed 76 distinct interaction features (Supplementary Table S1) distributed across nine categories:

- Interaction types (12 features, e.g. protein complex, transcriptional regulation)
- Source databases (19 features, e.g. KEGG, CORUM; containing interactions from different technologies and qualities of data and curation)
- Cancer-related pathways (28 features, e.g. Wnt signaling)
- Mutual exclusivity of mutations to source and target (one feature)
- Mutation rates of source and target genes (two features)
- Association between incidence of mutation and subtypes (two features denote associations between source or target gene and its most significantly associated subtype among all subtypes)
- Source or target gene is in top five most recurrently mutated (10 features)
- Self-loop (one feature)

- Intercept (one feature, constant term inside the Equation (3) sigmoid function)

All features were re-scaled to have similar range [0, 1], a common technique used in machine learning (Bishop, 2007). In particular, feature x is re-scaled to $(x - \min(x)) / (\max(x) - \min(x))$.

3 Results

In Section 3.1, we present the results of simulations to demonstrate the effect of minimizing the cost function during training and, more importantly, the intuition for why supervision is able to achieve improved results in comparison to unsupervised random walk. Next, in Sections 3.2 and 3.3, we apply the method to classify somatic mutation profiles of two major cancers cataloged in TCGA: glioblastoma (GBM) and breast cancer (BRCA).

3.1 Experiments on simulated data

3.1.1 Simulated data

To demonstrate and benchmark the NBS² algorithm, we simulated a molecular interaction network, edge features, and a tumor-by-gene matrix of mutation profiles where tumors belong to one of two subtypes that are not immediately separable by mutation profiles or network topology alone (Fig. 2A). Our goal was to recover these two subtypes as well as to detect their characteristic subnetworks.

We simulated somatic mutation profiles with 100 tumors and 1000 genes and divided the tumors into two equal-sized subtypes. Each subtype was assigned with 50 characteristic genes in the network. For each tumor, a unique characteristic gene was mutated (Fig. 2A); none of the two tumors shared the same characteristic gene, so that the two subtypes were completely indiscernible based on gene mutations. The characteristic genes were mutated with probability 1.5% (median mutation rate in 22 types of cancer in TCGA) among tumors within their respective subtype. Beyond mutations on the characteristic genes, other genes were randomly mutated with probability 1.5% to simulate passenger mutations in cancer. Finally, to simulate the influence of frequently mutated genes (FMG, e.g. *TTN*), we randomly assigned a gene with approximately 50% tumors mutated.

We simulated the molecular network used to guide the random walk using an Erdos-Renyi model (Erdos and Renyi, 1959). On this note, we found empirically that the particular method for generating random interactions, preferential attachment (Albert and Barabási, 2002) or Erdos-Renyi, did not have a large effect on the analysis and therefore chose a simpler model. Specifically, edges were randomly generated with probability 11.4% among the 100 characteristic genes and 0.4% for all other gene pairs, mimicking the connectivity between known cancer genes (Vogelstein *et al.*, 2013) and all other genes, respectively. Note that to better illustrate our results, edge density in Fig. 2B and C (70% for characteristic genes and 5% for others) is much higher than that in the actual simulation.

For each edge in the simulated network, the activation score (Equation 2) was determined by the following eight edge features: two subtype features, which were set to 1 for the edges between characteristic genes within the respective subtype, and 0 otherwise; two FMG features representing the incoming and outgoing edges from the FMG; two random features uniformly sampled from [0, 1]; a ‘self-loop’ feature as described above (Section 2.2); and an intercept term which was held constant at 1 for all edges.




Fig. 2. Experiments on simulated data. (A) Simulated mutation dataset including characteristic genes of two subtypes (genes 1–10) and a Frequently Mutated Gene (FMG) (gene 16). Mutated genes are shown in dark red and non-mutated genes are shown in white. A reduced set of tumors and genes (10×20) is shown as an example; the full simulation is 100×1000 . An edge-by-feature matrix is also used as an input for the supervised random walk. (B) Unsupervised and (C) supervised random walk of mutations over a simulated gene interaction network. Shades of red show propagated mutation values for tumor sample #7. (D, E) Propagated mutation profiles following (D) unsupervised and (E) supervised random walk. (F, G) Principal components analysis (PCA) of the full simulation (100×1000) between (F) unsupervised random walk-based tumor stratification and (G) supervised random walk-based tumor classification

3.1.2 Results of the simulation

We first assessed the performance of unsupervised RWR on the simulated dataset as a baseline. In this case, all edges were equally activated, so a random walk had equal probability to traverse to all neighbors of a specific node (Fig. 2B). Since the characteristic genes were highly connected within and between both subtypes, the final propagated mutation scores were evenly distributed across these genes and the two subnetworks remained unrecognizable (Fig. 2D). As a consequence, the unsupervised algorithm failed to recover the two simulated subtypes (Fig. 2F, accuracy = $51.0\% \pm 4.6\%$ in 10 simulations).

We next applied the NBS² algorithm to the simulated dataset. The supervised algorithm learned the underlying fact that the two subtype-characteristic edge features are very important and thus assign large positive weights to them (Table 1). Consequently, the two subtype-characteristic subnetworks emerged because the edge activation scores within each of these subnetworks were boosted (Fig. 2C). In contrast, the intercept term in the edge activation function was assigned a negative weight, which effectively removed

Table 1. Edge feature weights learned in simulation

Edge features	Feature weights
Subnetwork 1	7.84 ± 1.78
Subnetwork 2	7.89 ± 1.77
FMG (outgoing)	0.02 ± 0.10
FMG (incoming)	-0.05 ± 0.13
Random 1	-2.28 ± 3.18
Random 2	-0.49 ± 2.20
Self-loop	-0.82 ± 2.18
Intercept	-8.28 ± 2.74

edges between the subtype-characteristic subnetworks (activation score close to zero). All other edge features were typically assigned weights close to zero due to the l_1 regularization, indicating they were not important in identifying the two subtypes. As a result, the mutation signal was propagated far more avidly within each subnetwork than between subnetworks (Fig. 2E). Overall, our supervised random walk algorithm achieved nearly perfect classification in recovering the two simulated subtypes (Fig. 2G, accuracy = $91.5\% \pm 2.1\%$ in 10 simulations).

To further study the robustness of this method, we randomly flipped the subtype labels of either 10% or 20% of samples (adding noisy/wrong information) and measured the prediction accuracy. We found that accuracy dropped to $82.6\% \pm 2.7\%$ and $73.0\% \pm 6.6\%$, respectively, in 10 simulations. Interestingly, the edge feature weights were learned to have very similar values as the original simulation (Pearson's r of feature weights = 0.98 and 0.99, respectively). These results indicate our algorithm is robust especially in recovering the correct feature weights for network propagation.

3.1.3 Choice of hyperparameters

We also used simulations to inform the choice of hyperparameters. We found that the NBS² algorithm was robust to the particular values of hyperparameter α , the random walk restart probability (Equation 1), and λ , the lasso regularization parameter (Equation 7). We achieved very similar results when α was within a range of 0.15 to 0.5 and λ was within a range of 0 to 0.2. However, we also noted that the hyperparameter β in the loss function (Equation 7) was not robust and needed to be fine-tuned for the algorithm to work properly; we achieved reasonable results in the range of 500–10 000. Overall, the best classification performance was achieved with $\alpha = 0.3$, $\lambda = 0.1$ and $\beta = 5000$. The performance of real tumor mutation profiles with respect to different choices of hyperparameters can be found in Supplementary Figure S1.

3.2 Classification of glioblastoma

Having benchmarked NBS² in simulation, we next applied it to classify tumor mutation profiles from cancer patients. Glioblastoma multiforme (GBM) is the most common brain cancer malignancy diagnosed in adults. Affected patients have a very poor prognosis with a median survival of one year (Ohgaki and Kleihues, 2005). Widespread differences in gene expression and DNA methylation have previously been reported in GBM, grouping GBM tumors into five subtypes: Glioma-CpG Island Methylator Phenotype (G-CIMP), Proneural, Neural, Classical and Mesenchymal (Verhaak et al., 2010; Brennan et al., 2013). These subtypes have been shown to associate with distinct neural lineages, ages, prognoses and responses to therapy. For instance, G-CIMP is associated with younger age of

diagnosis and better survival (Brennan et al., 2013); while the Classical subtype is the most responsive to aggressive therapy (Verhaak et al., 2010). Our goal here was to not only classify the five GBM subtypes based on tumor mutation profiles, but also to identify the underlying gene interactions driving such types on a reference molecular network.

3.2.1 Glioblastoma data processing

We collected and integrated somatic mutation and copy number alteration (CNA) data of 223 GBM tumors (Brennan et al., 2013) as follows: A gene was considered altered if it had a non-silent somatic mutation, if it was a well-defined oncogene or tumor suppressor (Vogelstein et al., 2013), or if it fell within a CNA. We then divided the tumors into a training set (150 tumors) and a validation set (73 tumors). As a reference molecular network we used Pathway Commons (Cerami et al., 2011), documenting 968 186 pairwise relations among 15 485 human gene products pertaining to previously reported protein-protein, transcriptional and metabolic interactions. To focus on driver mutations, we removed all genes that were neither previously reported as cancer genes (Futreal et al., 2004; Vogelstein et al., 2013; Iorio et al., 2016) nor were in cancer-related pathways (Zhang et al., 2013), as well as genes which were mutated in fewer than four tumors in the training set (we observed that such filtering led to a $\sim 5\%$ improvement in accuracy of predictions and ~ 20 -fold improvement in running time). This approach resulted in a pruned network with 51 nodes (genes) and 296 edges (gene interactions). We designed 76 edge features based on annotations of interactions and mutation profiles of the training set as described in Section 2.6 (Supplementary Table S1).

3.2.2 Performance of subtype classification of glioblastoma tumors

We next sought to evaluate the predictive performance of the NBS² algorithm on the GBM data. We conducted a three-fold cross validation within the training set to tune hyperparameters, after which we used the complete training set for building the classifier and the remaining set of 73 tumors for validation. We noticed a strong anti-correlation between cost and accuracy, confirming that the cost function translates well to the goal of accurate classification (Fig. 3A). The training accuracy started at 34% at iteration 0 and increased to a plateau of 55–57% in about 60 iterations (Fig. 3A). Notably, validation accuracy also increased from 47 to 64%, indicating the model generalizes well on new data (Fig. 3B). The precision and recall were very high for G-CIMP, Classical, Mesenchymal and Proneural (54–100%), but poor for the Neural subtype (Table 2). This result is consistent with a previous report that the Neural subtype has very few, if any, characteristic mutations or copy number alterations (Verhaak et al., 2010). We also compared this validation performance to the baselines achieved by our previous NBS method (Hofree et al., 2013) (based on RWR) and through direct use of mutation profiles without random walk. In particular, to achieve two baseline performance scores we calculated the cluster centroids of the training set to make predictions of the validation set, just as what we did in Section 2.5. Both baseline methods achieved 47% in validation accuracy, a performance 17% lower than that of NBS² (Fig. 3B).

3.2.3 Characteristic subnetworks for glioblastoma subtypes

At convergence, the weighted network was of particular interest as it revealed characteristic mutated subnetworks underlying the five GBM subtypes. For instance, the Classical subtype was known to be characterized by *EGFR* mutations and copy number amplifications

(Verhaak *et al.*, 2010; Brennan *et al.*, 2013). The characteristic subnetwork revealed by NBS² recovers these characteristics along with additional genes, revealing a ‘EGFR-LAMA1-PIK3CA-LRP2’ subnetwork (Fig. 4A). In particular, Integrin-Laminin interaction (Laminin is partially encoded by *LAMA1*) is regulated by EGFR (Rabinovitz *et al.*, 1999) and can activate PI3K (partially encoded by *PIK3CA*) during cancer cell migration (Shaw *et al.*, 1997). Separately, PI3K regulates low density lipoprotein-related protein 2 (encoded by *LDL2*) in Clathrin-mediated endocytosis (Kirchhausen *et al.*, 2014). These interactions together identify a pathway related to motility and invasiveness of cancer cells.

Similarly, the G-CIMP subtype was reported to have characteristic somatic mutations at *IDH1* and *ATRX* (Verhaak *et al.*, 2010; Brennan *et al.*, 2013). Our analysis recovered these genes within a larger ‘*ABCB1-RB1-ATRX*’ subnetwork (Fig. 4A). *ABCB1* encodes a ATP-binding cassette transporter well-known to be involved in doxorubicin resistance in cancer therapy (Bray *et al.*, 2010). *RB*, encoded by *RB1*, has been recognized to play important roles in doxorubicin-induced senescence of breast cancer cells (Jackson and

Pereira-Smith, 2006). Thus, mutations on *ABCB1* may regulate *RB* in tumors treated with doxorubicin. *RB* is also a known transcriptional repressor of cell cycle, which can control the expression of *ATRX*, a chromatin remodeler, through inhibition of *E2F1* (Gerstein *et al.*, 2012).

The recovered subnetworks were reasonably stable across five different splits of the training/validation data: 9/18 signature genes were selected in most (≥ 3) splits, while 7/18 were selected in all (5) splits.

Another interesting finding concerns the interactions removed from the network by the NBS² algorithm (i.e. heavily down-weighted), including the three molecular interactions *IDH1-EGFR*, *TP53-EGFR* and *MDM2-TP53* (Fig. 4A). The four genes connected by these interactions are characteristic of different subtypes: *IDH1* is almost exclusively mutated in G-CIMP; *EGFR* alterations are enriched in the Classical subtype; *TP53* is recurrently mutated in G-CIMP and Proneural subtypes but lacks mutations in the Classical subtype; and *MDM2* mutations are enriched in both Proneural and Neural subtypes (Fig. 4B). Given these events define different subtypes during training, the algorithm has learned to prohibit sharing of mutation information across these interactions. Remarkably, the mutations of these three gene pairs are all mutually exclusive (Fig. 4B, Fisher’s exact test $P < 0.001$), a feature that has been used extensively to prioritize functionally related cancer genes (Ciriello *et al.*, 2012). Previous studies (Leiserson *et al.*, 2015b) demonstrated that mutual exclusivity can arise as a consequence of two cancer subtypes with different characteristic alterations. Our results confirm such observation: the mutual exclusivity among these genes may be driven not by functional similarity of mutations but by the genomically and functionally distinct nature of different subtypes. In addition, our method also provides a systematic way to differentiate whether or not mutual exclusivity of a pair of genes is due to cancer evolutionary pressure.

When we examined the interaction feature weights, we found that ‘Epithelial-mesenchymal transition (EMT)’ and ‘Mutual exclusivity’ were assigned large positive values, suggesting that propagating mutations through interactions marked by EMT-pathway and Mutual-Exclusivity features is favorable for stratification. ‘Mutation rate of the target gene’ was assigned a large negative weight, indicating that random walks from a rarely mutated gene to a recurrently mutated gene was not favorable.

3.3 Classification of breast cancer

As a second case study we examined breast cancer, a heterogeneous disease that has been previously stratified into four subtypes—Basal, Her2, Luminal A and Luminal B—based on molecular alterations, cellular composition and/or clinical outcomes (Prat and Perou, 2011). For instance, the Her2 subtype is characterized by *ERBB2* amplification and poor prognosis, whereas the Luminal A subtype is




Fig. 3. Performance of glioblastoma subtype classification. Values of cost function (left y-axis) and classification accuracy (right y-axis) are plotted against the number of iterations of NBS² on the (A) training data and (B) validation data. Dashed line indicates accuracy of tumor stratification based on unsupervised random walk and non-propagated mutation profiles (equal values, slight offset in accuracy is for visualization)

Table 2. Glioblastoma validation performance

		Predicted					
		Classical	G-CIMP	Mesenchymal	Neural	Proneural	
Subtype as defined previously by expression	Classical	17	0	3	0	4	24
	G-CIMP	0	6	0	0	1	7
	Mesenchymal	3	0	16	1	0	20
	Neural	3	0	5	1	1	10
	Proneural	2	0	2	1	7	12
		25	6	26	3	13	




Fig. 4. Subnetworks for glioblastoma subtypes. (A) (<http://www.ndexbio.org/#/network/3a5206c2-fd4e-11e7-adc1-0ac135e8bacf>) Subnetworks characterizing glioblastoma subtypes extracted from Pathway Commons by NBS². The subnetworks are defined by the set of genes for which the propagated mutation score is significantly different across subtypes (ANOVA False Discovery Rate < 0.30) and the set of interactions for which the activation score is above average (> 0.04). The pie chart represents the relative proportions of the average propagated mutation score for the five subtypes. For example, the large blue pie slice on IDH1 indicates that its average propagation score is much higher in G-CIMP tumors than other subtypes. (B) Mutation profiles and subtype assignments of individual tumors (columns) associated with genes *EGFR*, *IDH1*, *MDM2* and *TP53* (rows)

characterized by normal estrogen receptor (ER positive), low tumor grade, good prognosis and low risk of relapse. These subtypes have been intensively studied and repeatedly identified by clustering of mRNA expression data (Perou et al., 2000; Parker et al., 2009).

3.3.1 Breast cancer data processing

We collected somatic mutation and copy number alteration (CNA) data from 863 breast tumors (Cancer Genome Atlas Network, 2012; Ciriello et al., 2015) which we divided into a training (577 tumors) and a validation set (286 tumors). The data were then pre-processed as for GBM, resulting in a pruned network with 557 nodes (genes) and 16 590 edges (interactions). For each edge, we generated the same 76 features as in the GBM network (Sections 2.6 and 3.2.1, Supplementary Table S1).




Fig. 5. Performance of breast cancer subtype classification. Values of cost function (left y-axis) and classification accuracy (right y-axis) are plotted against the number of iterations of NBS² on the (A) training data and (B) validation data. Dashed line indicates the accuracy of tumor stratification based on unsupervised random walk and non-propagated mutation profiles

3.3.2 Performance of breast cancer subtype classification

We evaluated predictive performance on the breast cancer data in a similar way as we did for GBM. During training, the algorithm converged in about 200 iterations and achieved approximately 70% classification accuracy (Fig. 5A). The accuracy of the 286-tumor validation set also increased from 53% to 68% (Fig. 5B). Notably, the prediction performance of BRCA was better than that of GBM. The main reason is that 50% of BRCA samples are of type Luminal A, indicating that a naive classifier could achieve a baseline of 50% accuracy simply by always predicting this subtype label. The GBM subtypes are more balanced, resulting in a lower baseline prediction accuracy around 32% (Supplementary Table S2). Importantly, the gain in prediction accuracy (10–20%) is very significant for both tissues. The precision and recall were very good for Basal and Luminal A (66–79%, Table 3) and acceptable for the HER2 subtype (precision = 46%, recall = 60%). The recall was a bit lower for Luminal B (35%), in which 24 tumors were mistakenly predicted as Luminal A. This is understandable as the Luminal cancers are the most heterogeneous in terms of mutation spectrum (Cancer Genome Atlas Network, 2012). We next compared this validation accuracy to the baselines achieved by unsupervised RWR (53%) or mutation profiles (56%). Overall NBS² achieved a 12–15% improvement over baseline methods (Fig. 5B).

3.3.3 Characteristic subnetworks of breast cancer subtypes

At convergence, the weighted interactions revealed subtype-characteristic subnetworks (Fig. 6A). The resultant subnetworks were stable across five different splits of the training/validation data: 18/30 genes were selected in most (≥ 3) splits, while 9/30 were selected in all (5) splits. The Luminal A subtype was characterized by a 10-gene subnetwork centered on *PIK3CA*, *CDH1*, *CCND1* and *NOTCH1*. These genes were highly interconnected, indicating synergies between their mutations: for example, Cadherin 1

Table 3. Breast cancer validation performance

		Predicted				
		Basal	HER2	Lum A	Lum B	
Subtype as defined previously by expression	Basal	40	1	8	4	53
	HER2	3	12	2	3	20
	LUM A	10	6	121	16	153
	LUM B	8	7	24	21	60
		61	26	155	44	




Fig. 6. Subnetworks of breast cancer subtypes. (A) (<http://www.ndexbio.org/#/network/dd268e2f-fd4d-11e7-adc1-0ac135e8bacf>) Subnetworks characterizing breast cancer subtypes extracted from Pathway Commons by NBS², defined as for GBM in Figure 4. (B) Mutation profiles and subtype assignments of individual tumors (columns) associated with genes *TP53*, *ERBB2*, *PIK3CA*, *CDH1* and *MYC* (rows)

(encoded by *CDH1*) does not only activate PI3K (partially encoded by *PIK3CA*) (Xie and Bikle, 2007), but also interacts with and degrades cyclin D1 (encoded by *CCND1*) (Pawar et al., 2010), which regulates cell cycle. Beyond the interactions with *CDH1*, PI3K is required for expression of cyclin D1 (Ye et al., 2000). This subnetwork also linked to Notch1, which forms a complex with PI3K (Sade et al., 2004) and, separately, promotes the reduction of E-cadherin levels (Fujiki et al., 2014).

A second subnetwork of interest, characterizing both Basal and HER2 subtypes, contained interactions between *TP53*, *EGFR*, *NOTCH4* and *MET*. P53 (encoded by *TP53*) transcriptionally activates oncogenes *EGFR* (Ludes-Meyers et al., 1996) and c-met (encoded by *MET*) (Seol et al., 1999). Separately, P53 also suppresses Notch4-associated tumorigenesis (Sun et al., 2011). The mutations on these genes may thus be functionally related in Basal/HER2 cancers.

Many of the interactions that were removed connect genes characterizing different subtypes, including *TP53-PIK3CA*, *TP53-MYC*, *ERBB2-PIK3CA* and *ERBB2-CDH1*. As described above, *TP53* mutations characterize Basal and HER2 subtypes; *PIK3CA* and *CDH1* mutations characterize the Luminal A subtype. In addition, *ERBB2* amplification defines the HER2 subtype; and *MYC* amplification is enriched in Basal and Luminal B subtypes (Fig. 4C). Similar to the GBM network, traversal through these interactions was prohibited during supervised learning so as to avoid cross-contamination between different subtype-characteristic mutation signals.

In terms of interaction features, we found that ‘CORUM’ (the protein complex database) and ‘Epithelial-mesenchymal transition (EMT)’ were assigned the largest positive weights, and ‘Intercept’ was assigned the largest negative weight. These weights indicated that random walks were generally prohibited for all edges except for those supported by select edge features such as high-quality protein complexes or known interactions in the EMT pathway.

4 Discussion

We have presented Network-Based Supervised Stratification (NBS²), a supervised random walk algorithm for cancer subtype classification. Given a reference molecular network and tumor mutation profiles, NBS² learns a strategy to guide the direction of network propagation for better subtype classification. Case studies on glioblastoma and breast tumors demonstrated that NBS² significantly outperforms state-of-the-art unsupervised methods. By dissecting the learned model, NBS² was able to highlight underlying biological pathways characteristic of cancer subtypes.

In future, we anticipate that NBS² can be extended in several ways. First, from a computational point of view, the linear scoring function of features could be replaced by a non-linear function (e.g. neural network) to capture more complicated relationships between genetic features and clinical measurements. Second, although our analysis focused on glioblastoma and breast cancer, the methodology is general and could be applied to other cancer types or complex diseases in which information on somatic mutations or inherited variants is available. Furthermore, the method is extensible to other types of ‘omics’ data such as gene expression, epigenomics, proteomic and metabolic profiles and so on.

From a biological perspective, gene expression-based cancer subtypes have been extensively studied as they are sometimes associated with distinct molecular, cellular, clinical and therapeutic characteristics (Brennan *et al.*, 2013; Prat and Perou, 2011; Cancer Genome Atlas Research Network, 2011; Li *et al.*, 2009). However, it has been a long standing challenge to connect such expression patterns to their underlying mechanistic basis, that is, the genetic alterations that drive them. In this study, the networks identified by NBS² create bridges between mutations and gene expression-based subtypes in GBM and BRCA.

Finally, our results provide an important counterexample of the notion that mutual exclusivity always indicates co-function within a pathway (Ciriello *et al.*, 2012). Here, we found that it is sometimes driven by the genomically and functionally distinct nature of different subtypes.

Acknowledgements

The results are in whole or part based upon data generated by the TCGA: <http://cancergenome.nih.gov/>. Networks (Figs. 4A and 6A) have been deposited to NDEx (Pillich *et al.*, 2017; Pratt *et al.*, 2015, 2017). We would like to thank members of the Ideker laboratory for valuable comments on this work.

Funding

This work was supported by NIH grants to T.I. (U24CA184427, U54CA209891, P50GM085764, P41GM103504 and R01GM070743).

Conflict of Interest: Trey Ideker is co-founder of Data4Cure, Inc. and has an equity interest. Trey Ideker has an equity interest in Ideaya BioSciences, Inc. The terms of this arrangement have been reviewed and approved by the University of California, San Diego, in accordance with its conflict of interest policies. No potential conflicts of interest were disclosed by the other authors.

References

- Albert, R. and Barabási, A.-L. (2002) Statistical mechanics of complex networks. *Rev. Mod. Phys.*, **74**, 47–97.
- AlQuraishi, M. *et al.* (2014) A multiscale statistical mechanical framework integrates biophysical and genomic data to assemble cancer networks. *Nat. Genet.*, **46**, 1363–1371.
- Backstrom, L. and Leskovec, J. (2010) Supervised random walks: predicting and recommending links in social networks. *arXiv:1011.4071*.
- Bertrand, D. *et al.* (2015) Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles. *Nucleic Acids Res.*, **43**, e44.
- Bishop, C. (2007) *Pattern Recognition and Machine Learning (Information Science and Statistics)*, 1st edn. 2006. corr. 2nd printing edn. Springer, New York.
- Bray, J. *et al.* (2010) Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. *Br. J. Cancer*, **102**, 1003–1009.
- Brennan, C.W. *et al.* (2013) The somatic genomic landscape of glioblastoma. *Cell*, **155**, 462–477.
- Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. *Nature*, **490**, 61–70.
- Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. *Nature*, **474**, 609–615.
- Cerami, E.G. *et al.* (2011) Pathway commons, a web resource for biological pathway data. *Nucleic Acids Res.*, **39**, D685–D690.
- Cho, A. *et al.* (2016) MUFFINN: cancer gene discovery via network analysis of somatic mutation data. *Genome Biol.*, **17**, 129.
- Ciriello, G. *et al.* (2015) Comprehensive molecular portraits of invasive lobular breast cancer. *Cell*, **163**, 506–519.
- Ciriello, G. *et al.* (2012) Mutual exclusivity analysis identifies oncogenic network modules. *Genome Res.*, **22**, 398–406.
- Cowen, L. *et al.* (2017) Network propagation: a universal amplifier of genetic associations. *Nat. Rev. Genet.*, **18**, 551–562.
- Creixell, P. *et al.* (2015a) Unmasking determinants of specificity in the human kinome. *Cell*, **163**, 187–201.
- Creixell, P. *et al.* (2015b) Pathway and network analysis of cancer genomes. *Nat. Methods*, **12**, 615–621.
- Creixell, P. *et al.* (2015c) Kinome-wide decoding of network-attacking mutations rewiring cancer signaling. *Cell*, **163**, 202–217.
- Erdos, P. and Renyi, A. (1959) On random graphs I. *Publ. Math. Debrecen.*, **6**, 290–297.
- Fujiki, K. *et al.* (2014) Detrimental effects of Notch1 signaling activated by cadmium in renal proximal tubular epithelial cells. *Cell Death Dis.*, **5**, e1378.
- Futreal, P.A. *et al.* (2004) A census of human cancer genes. *Nat. Rev. Cancer*, **4**, 177–183.
- Gaiteri, C. *et al.* (2015) Identifying robust communities and multi-community nodes by combining top-down and bottom-up approaches to clustering. *Sci. Rep.*, **5**, 16361.
- Gerstein, M.B. *et al.* (2012) Architecture of the human regulatory network derived from ENCODE data. *Nature*, **489**, 91–100.
- Hofree, M. *et al.* (2013) Network-based stratification of tumor mutations. *Nat. Methods*, **10**, 1108–1115.
- Horn, H. *et al.* (2018) NetSig: network-based discovery from cancer genomes. *Nat. Methods*, **15**, 61–66.
- International Cancer Genome Consortium. *et al.* (2010) International network of cancer genome projects. *Nature*, **464**, 993–998.
- Iorio, F. *et al.* (2016) A landscape of pharmacogenomic interactions in cancer. *Cell*, **166**, 740–754.
- Jackson, J.G. and Pereira-Smith, O.M. (2006) Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells. *Mol. Cell Biol.*, **26**, 2501–2510.
- Jin, N. *et al.* (2015) Network-based survival-associated module biomarker and its crosstalk with cell death genes in ovarian cancer. *Sci. Rep.*, **5**, 11566.
- Kim, Y.-A. *et al.* (2016) Understanding genotype-phenotype effects in cancer via network approaches. *PLoS Comput. Biol.*, **12**, e1004747.
- Kingma, D.P. and Ba, J. (2014) Adam: a method for stochastic optimization. *arXiv:1412.6980*.
- Kirchhausen, T. *et al.* (2014) Molecular structure, function, and dynamics of clathrin-mediated membrane traffic. *Cold Spring Harb. Perspect. Biol.*, **6**, a016725.
- Leiserson, M.D.M. *et al.* (2015a) Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. *Nat. Genet.*, **47**, 106–114.
- Leiserson, M.D.M. *et al.* (2015b) CoMET: a statistical approach to identify combinations of mutually exclusive alterations in cancer. *Genome Biol.*, **16**, 160.
- Li, Z. *et al.* (2009) Gene expression-based classification and regulatory networks of pediatric acute lymphoblastic leukemia. *Blood*, **114**, 4486–4493.
- Li, Z. *et al.* (2017) The OncoPPi network of cancer-focused protein–protein interactions to inform biological insights and therapeutic strategies. *Nat. Commun.*, **8**, 14356.
- Ludes-Meyers, J.H. *et al.* (1996) Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. *Mol. Cell Biol.*, **16**, 6009–6019.
- Miller, C.A. *et al.* (2011) Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors. *BMC Med. Genomics*, **4**, 34.
- Ohgaki, H. and Kleihues, P. (2005) Epidemiology and etiology of gliomas. *Acta Neuropathol.*, **109**, 93–108.
- Parker, J.S. *et al.* (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. *J. Clin. Oncol.*, **27**, 1160–1167.
- Pawar, S.A. *et al.* (2010) C/EBP δ targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression. *Proc. Natl. Acad. Sci. USA*, **107**, 9210–9215.

- Pearson, K. (1905) The problem of the random walk. *Nature*, **72**, 342.
- Perou, C.M. *et al.* (2000) Molecular portraits of human breast tumours. *Nature*, **406**, 747–752.
- Pillich, R.T. *et al.* (2017) NDEx: a community resource for sharing and publishing of biological networks. *Methods Mol. Biol.*, **1558**, 271–301.
- Prat, A. and Perou, C.M. (2011) Deconstructing the molecular portraits of breast cancer. *Mol. Oncol.*, **5**, 5–23.
- Pratt, D. *et al.* (2017) NDEx 2.0: a clearinghouse for research on cancer pathways. *Cancer Res.*, **77**, e58–e61.
- Pratt, D. *et al.* (2015) NDEx, the network data exchange. *Cell Syst.*, **1**, 302–305.
- Rabinovitz, I. *et al.* (1999) Protein kinase C-dependent mobilization of the $\alpha 6 \beta 4$ integrin from hemidesmosomes and its association with actin-rich cell protrusions drive the chemotactic migration of carcinoma cells. *J. Cell Biol.*, **146**, 1147–1160.
- Ruffalo, M. *et al.* (2015) Network-based integration of disparate omic data to identify ‘silent players’ in cancer. *PLoS Comput. Biol.*, **11**, e1004595.
- Sade, H. *et al.* (2004) The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. *J. Biol. Chem.*, **279**, 2937–2944.
- Seol, D.W. *et al.* (1999) Regulation of the c-met proto-oncogene promoter by p53. *J. Biol. Chem.*, **274**, 3565–3572.
- Shaw, L.M. *et al.* (1997) Activation of phosphoinositide 3-OH kinase by the $\alpha 6 \beta 4$ integrin promotes carcinoma invasion. *Cell*, **91**, 949–960.
- Sun, Y. *et al.* (2011) Trp53 regulates Notch 4 signaling through Mdm2. *J. Cell Sci.*, **124**, 1067–1076.
- Verhaak, R.G.W. *et al.* (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell*, **17**, 98–110.
- Vogelstein, B. *et al.* (2013) Cancer genome landscapes. *Science*, **339**, 1546–1558.
- Weinstein, J.N. *et al.* (2013) The cancer genome atlas pan-cancer analysis project. *Nat. Genet.*, **45**, 1113–1120.
- Wu, X. *et al.* (2009) Pattern discovery in breast cancer specific protein interaction network. *Summit. Transl. Bioinform.*, **2009**, 1–5.
- Xie, Z. and Bikle, D.D. (2007) The recruitment of phosphatidylinositol 3-kinase to the E-cadherin-catenin complex at the plasma membrane is required for calcium-induced phospholipase C- $\gamma 1$ activation and human keratinocyte differentiation. *J. Biol. Chem.*, **282**, 8695–8703.
- Yan, L. *et al.* (2003) Optimizing classifier performance via an approximation to the Wilcoxon–Mann–Whitney statistic. *Proceedings of the 20th International Conference on Machine Learning (ICML-03)*, pp. 848–855.
- Ye, K. *et al.* (2000) Pike. A nuclear gtpase that enhances PI3kinase activity and is regulated by protein 4.1N. *Cell*, **103**, 919–930.
- Zhang, W. *et al.* (2013) Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer. *Cell Rep.*, **4**, 542–553.